EQMS market for pharma and medtech to reach $5.22 billion by 2030

The Business Research Company says the electronic quality management system market for pharma and medtech will rise from $2.9 billion in 2025 to $3.27 billion in 2026, as regulatory pressure and digital quality tools accelerate adoption. The report projects the market will reach $5.22 billion by 2030, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - Pharma and medtech companies are under more pressure to prove compliance, keep cleaner records and move faster on quality issues. - EQMS platforms help centralize audits, CAPA, document control, training and compliance monitoring in regulated life sciences settings. - The market outlook suggests quality software is becoming a core operational tool rather than a back-office add-on.

What happened: - The Business Research Company released its Electronic Quality Management System (EQMS) For Pharma And Medtech Global Market Report 2026. - The report values the market at $2.9 billion in 2025 and projects $3.27 billion in 2026. - The report forecasts the market will reach $5.22 billion by 2030. - North America held the largest share of the market in 2025. - Asia-Pacific is projected to post the fastest growth over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - The 2025-to-2026 growth rate is 12.8%. - The 2026-to-2030 growth rate is projected at 12.4%. - The report points to tighter regulatory oversight, wider use of digital quality documentation, stronger CAPA management and improved audit readiness as drivers of recent growth. - Expected growth drivers include cloud-based EQMS adoption, investment in predictive quality and risk management, integrated supplier quality tools and automated compliance monitoring. - Key trends include centralized quality event management, automated CAPA workflows, digital document control, version management, audit management and employee training tracking. - The report defines EQMS as a digital platform that manages quality events, deviations, CAPA, document control, audits, compliance monitoring and training. - Regulatory inspections and audits are identified as a major demand driver because health authorities are increasing scrutiny of quality and safety requirements. - In March 2024, IFIAR reported an increase in findings across all five inspection areas in its annual survey. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market forecast reflects a broader shift in life sciences toward more automated quality management and faster regulatory response. - The emphasis on predictive quality, risk management and supplier tools suggests buyers want systems that do more than store compliance records. - Faster growth in Asia-Pacific points to expanding digital maturity and regulatory investment outside the market's current North American base.

What's next: - EQMS adoption is likely to expand as companies look for stronger audit readiness and tighter control over quality workflows. - Cloud deployment and automation are positioned to remain the main technology themes through 2030. - The report says training and qualification tracking will become more important as regulated companies widen system use across quality operations.

The bottom line: - EQMS is moving deeper into the core quality stack for pharma and medtech, with sustained double-digit growth expected through 2030.